You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
Moodys
Johnson and Johnson
AstraZeneca
Dow

Last Updated: May 8, 2021

DrugPatentWatch Database Preview

PEMFEXY Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Pemfexy patents expire, and when can generic versions of Pemfexy launch?

Pemfexy is a drug marketed by Eagle Pharms and is included in one NDA. There are two patents protecting this drug.

This drug has twenty-five patent family members in fourteen countries.

The generic ingredient in PEMFEXY is pemetrexed. There are twenty-nine drug master file entries for this compound. Additional details are available on the pemetrexed profile page.

DrugPatentWatch® Generic Entry Outlook for Pemfexy

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 28, 2035. This may change due to patent challenges or generic licensing.

There have been thirteen patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are fifteen tentative approvals for the generic drug (pemetrexed), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

< Available with Subscription >

  Get Started for $10

Summary for PEMFEXY
International Patents:25
US Patents:2
Applicants:1
NDAs:1
Clinical Trials: 1
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for PEMFEXY
DailyMed Link:PEMFEXY at DailyMed
Drug patent expirations by year for PEMFEXY
DrugPatentWatch® Estimated Generic Entry Opportunity Date for PEMFEXY
Generic Entry Date for PEMFEXY*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for PEMFEXY

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Novartis PharmaceuticalsPhase 3

See all PEMFEXY clinical trials

US Patents and Regulatory Information for PEMFEXY

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eagle Pharms PEMFEXY pemetrexed SOLUTION;INTRAVENOUS 209472-001 Feb 8, 2020 RX Yes Yes   Get Started for $10   Get Started for $10   Get Started for $10
Eagle Pharms PEMFEXY pemetrexed SOLUTION;INTRAVENOUS 209472-001 Feb 8, 2020 RX Yes Yes   Get Started for $10   Get Started for $10 Y   Get Started for $10
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for PEMFEXY

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0432677 7/2005 Austria   Get Started for $10 PRODUCT NAME: PEMETREXED UND DESSEN PHARMAZEUTISCH ANNAHMBAREN SALZE; REGISTRATION NO/DATE: EU/1/04/290/001 20040920
0432677 SPC/GB05/011 United Kingdom   Get Started for $10 PRODUCT NAME: PEMETREXED AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/04/290/001 20040920
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Mallinckrodt
McKinsey
Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.